At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot, Effect of Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) on Post-Treatment Lyme Disease Syndrome
In Brief
A clinical study evaluating respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) and Sham RAVANS for Post-Treatment Lyme Disease Syndrome. Completed, enrolled 15 participants.
Detailed Summary
This study is to assess if respiratory-gated auricular vagal nerve stimulation (RAVANS) can improve symptoms of post-treatment Lyme disease syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Treatment Lyme Disease Syndrome
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartMay 2022
Primary CompletionAug 2024
Study CompletionApr 2025
TodayJul 2026
First PostedJun 24, 2021
Enrollment StartMay 31, 2022
Primary CompletionAug 11, 2024
Study CompletionApr 25, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.0 years ago
Interventions
respiratory-gated auricular vagal afferent nerve stimulation (RAVANS)device
non-painful electrical stimulation of the auricle
Sham RAVANSdevice
sham stimulation